Cargando…

Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients

Objectives: There have been limited studies concerning the safety and efficacy of linezolid (LZD) in children. This study aimed to evaluate the association between LZD exposure and clinical safety and efficacy in Chinese pediatric patients. Methods: This retrospective cross-sectional study included...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Ben-Nian, Wu, Yue-E., Shu, Ling, Zhang, Ruo-Qi, Xiao, Jian-Wen, Li, Qian-Bo, Zhao, Wei, Jia, Yun-Tao, Song, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377148/
https://www.ncbi.nlm.nih.gov/pubmed/35979237
http://dx.doi.org/10.3389/fphar.2022.926711
_version_ 1784768281672941568
author Huo, Ben-Nian
Wu, Yue-E.
Shu, Ling
Zhang, Ruo-Qi
Xiao, Jian-Wen
Li, Qian-Bo
Zhao, Wei
Jia, Yun-Tao
Song, Lin
author_facet Huo, Ben-Nian
Wu, Yue-E.
Shu, Ling
Zhang, Ruo-Qi
Xiao, Jian-Wen
Li, Qian-Bo
Zhao, Wei
Jia, Yun-Tao
Song, Lin
author_sort Huo, Ben-Nian
collection PubMed
description Objectives: There have been limited studies concerning the safety and efficacy of linezolid (LZD) in children. This study aimed to evaluate the association between LZD exposure and clinical safety and efficacy in Chinese pediatric patients. Methods: This retrospective cross-sectional study included patients ≤18 years of age who received ≥3 days of LZD treatment between 31 January 2015, and 31 December 2020. Demographic characteristics, medication information, laboratory test information, and bacterial culture results were collected from the Hospital Information System (HIS). Exposure was defined as AUC(24) and calculated by the non-linear mixed-effects modeling program (NONMEM), version 7.2, based on two validated population pharmacokinetic models. Binary logistic regression analyses were performed to analyze the associations between AUC(24) and laboratory adverse events, and receiver operating characteristic curves were used to calculate the cut-off values. Efficacy was evaluated by bacterial clearance. Results: A total of 413 paediatric patients were included, with an LZD median (interquartile range) dose, duration, clearance and AUC(24) of 30.0 (28.1-31.6) mg/kg/day, 8 (4‒15) days,1.31 (1.29-1.32) L/h and 81.1 (60.6-108.7) mg/L·h, respectively. Adverse events associated with TBil, AST, ALT, PLT, hemoglobin, WBC, and neutrophil count increased during and after LZD treatment when compared with before medication (p < 0.05), and the most common adverse events were thrombocytopaenia (71/399, 17.8%) and low hemoglobin (61/401, 15.2%) during the LZD treatment. Patients with AUC(24) higher than 120.69 mg/L h might be associated with low hemoglobin 1–7 days after the end of the LZD treatment, and those with an AUC(24) higher than 92.88 mg/L∙h might be associated with thrombocytopaenia 8–15 days after the end of the LZD treatment. A total of 136 patients underwent bacterial culture both before and after LZD treatment, and the infection was cleared in 92.6% (126/136) of the patients, of whom 69.8% (88/126) had AUC(24)/MIC values greater than 80. Conclusion: Hematological indicators should be carefully monitored during LZD treatment, especially thrombocytopaenia and low hemoglobin, and a continuous period of monitoring after LZD withdrawal is also necessary. Since the AUC(24) cut-off values for laboratory adverse events were relatively low, a trade-off is necessary between the level of drug exposure required for treatment and safety, and the exposure target (AUC(24)/MIC) in pediatric patients should be further studied, especially for patients with complications and concomitant medications.
format Online
Article
Text
id pubmed-9377148
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93771482022-08-16 Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients Huo, Ben-Nian Wu, Yue-E. Shu, Ling Zhang, Ruo-Qi Xiao, Jian-Wen Li, Qian-Bo Zhao, Wei Jia, Yun-Tao Song, Lin Front Pharmacol Pharmacology Objectives: There have been limited studies concerning the safety and efficacy of linezolid (LZD) in children. This study aimed to evaluate the association between LZD exposure and clinical safety and efficacy in Chinese pediatric patients. Methods: This retrospective cross-sectional study included patients ≤18 years of age who received ≥3 days of LZD treatment between 31 January 2015, and 31 December 2020. Demographic characteristics, medication information, laboratory test information, and bacterial culture results were collected from the Hospital Information System (HIS). Exposure was defined as AUC(24) and calculated by the non-linear mixed-effects modeling program (NONMEM), version 7.2, based on two validated population pharmacokinetic models. Binary logistic regression analyses were performed to analyze the associations between AUC(24) and laboratory adverse events, and receiver operating characteristic curves were used to calculate the cut-off values. Efficacy was evaluated by bacterial clearance. Results: A total of 413 paediatric patients were included, with an LZD median (interquartile range) dose, duration, clearance and AUC(24) of 30.0 (28.1-31.6) mg/kg/day, 8 (4‒15) days,1.31 (1.29-1.32) L/h and 81.1 (60.6-108.7) mg/L·h, respectively. Adverse events associated with TBil, AST, ALT, PLT, hemoglobin, WBC, and neutrophil count increased during and after LZD treatment when compared with before medication (p < 0.05), and the most common adverse events were thrombocytopaenia (71/399, 17.8%) and low hemoglobin (61/401, 15.2%) during the LZD treatment. Patients with AUC(24) higher than 120.69 mg/L h might be associated with low hemoglobin 1–7 days after the end of the LZD treatment, and those with an AUC(24) higher than 92.88 mg/L∙h might be associated with thrombocytopaenia 8–15 days after the end of the LZD treatment. A total of 136 patients underwent bacterial culture both before and after LZD treatment, and the infection was cleared in 92.6% (126/136) of the patients, of whom 69.8% (88/126) had AUC(24)/MIC values greater than 80. Conclusion: Hematological indicators should be carefully monitored during LZD treatment, especially thrombocytopaenia and low hemoglobin, and a continuous period of monitoring after LZD withdrawal is also necessary. Since the AUC(24) cut-off values for laboratory adverse events were relatively low, a trade-off is necessary between the level of drug exposure required for treatment and safety, and the exposure target (AUC(24)/MIC) in pediatric patients should be further studied, especially for patients with complications and concomitant medications. Frontiers Media S.A. 2022-08-01 /pmc/articles/PMC9377148/ /pubmed/35979237 http://dx.doi.org/10.3389/fphar.2022.926711 Text en Copyright © 2022 Huo, Wu, Shu, Zhang, Xiao, Li, Zhao, Jia and Song. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Huo, Ben-Nian
Wu, Yue-E.
Shu, Ling
Zhang, Ruo-Qi
Xiao, Jian-Wen
Li, Qian-Bo
Zhao, Wei
Jia, Yun-Tao
Song, Lin
Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients
title Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients
title_full Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients
title_fullStr Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients
title_full_unstemmed Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients
title_short Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients
title_sort relationship between linezolid exposure and the typical clinical laboratory safety and bacterial clearance in chinese pediatric patients
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377148/
https://www.ncbi.nlm.nih.gov/pubmed/35979237
http://dx.doi.org/10.3389/fphar.2022.926711
work_keys_str_mv AT huobennian relationshipbetweenlinezolidexposureandthetypicalclinicallaboratorysafetyandbacterialclearanceinchinesepediatricpatients
AT wuyuee relationshipbetweenlinezolidexposureandthetypicalclinicallaboratorysafetyandbacterialclearanceinchinesepediatricpatients
AT shuling relationshipbetweenlinezolidexposureandthetypicalclinicallaboratorysafetyandbacterialclearanceinchinesepediatricpatients
AT zhangruoqi relationshipbetweenlinezolidexposureandthetypicalclinicallaboratorysafetyandbacterialclearanceinchinesepediatricpatients
AT xiaojianwen relationshipbetweenlinezolidexposureandthetypicalclinicallaboratorysafetyandbacterialclearanceinchinesepediatricpatients
AT liqianbo relationshipbetweenlinezolidexposureandthetypicalclinicallaboratorysafetyandbacterialclearanceinchinesepediatricpatients
AT zhaowei relationshipbetweenlinezolidexposureandthetypicalclinicallaboratorysafetyandbacterialclearanceinchinesepediatricpatients
AT jiayuntao relationshipbetweenlinezolidexposureandthetypicalclinicallaboratorysafetyandbacterialclearanceinchinesepediatricpatients
AT songlin relationshipbetweenlinezolidexposureandthetypicalclinicallaboratorysafetyandbacterialclearanceinchinesepediatricpatients